Dutasteride Solid Preparation Using Porous Excipient
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Dutasteride's poor solubility in water and the instability of soft capsule formulations lead to delayed dissolution and high manufacturing costs, along with bioavailability issues in existing solid preparations, necessitating a solution that enhances solubility and bioavailability while maintaining pharmacokinetic parameters equivalent to AVODART soft capsules.
Innovation Solution
A solid preparation comprising a self-emulsifying composition of dutasteride, oil, and surfactant, coated with a porous excipient having a controlled pore structure, which facilitates rapid dissolution and bioavailability by forming a coating film that blocks narrow pores and allows quick release of the self-emulsifying composition in aqueous environments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If soft capsule formulation is used to improve dutasteride solubility, then bioavailability is enhanced, but manufacturing complexity and cost increase significantly
Solution Approach 1:
The patent changes the physical form of the drug from liquid (soft capsule) to solid (tablet) by incorporating dutasteride into a self-emulsifying composition that forms fine emulsion particles. This parameter change allows the drug to maintain high bioavailability through enhanced solubility while being manufacturable as a solid tablet, thus resolving the contradiction between bioavailability enhancement and manufacturing complexity
Solution Approach 2:
The patent creates a composite self-emulsifying composition containing dutasteride, oil, and surfactant that forms a fine emulsion particle structure. This composite material provides the solubility enhancement characteristics of liquid formulations while enabling solid tablet formulation, thereby resolving the contradiction between achieving high bioavailability and maintaining manufacturing simplicity
2Reliability
If soft capsule formulation is used to dissolve dutasteride, then solubility is improved, but dissolution is delayed due to gelatin and oil curing at low temperatures
Solution Approach 1:
The patent changes the formulation from a cured gelatin-oil matrix (soft capsule) to a self-emulsifying composition that forms fine emulsion particles. This parameter change eliminates the curing issue that delays dissolution, allowing rapid solubility enhancement upon contact with gastrointestinal fluids while maintaining high solubility, thus resolving the contradiction between solubility improvement and dissolution speed
3Ease of manufacture
If solid particles are made by adsorbing self-emulsifying composition to excipient, then manufacturing is simplified, but bioavailability is lower than soft capsule product
Solution Approach 1:
The patent uses a porous excipient (colloidal silicon dioxide) to which the self-emulsifying composition is adsorbed. The porous structure provides a large surface area for adsorption while maintaining the self-emulsifying properties. This approach simplifies manufacturing compared to soft capsules while achieving bioavailability equivalent to or greater than the soft capsule product through the fine emulsion particle structure, thus resolving the contradiction between manufacturing simplicity and bioavailability
4Ease of manufacture
If dutasteride is formulated as solid preparation, then manufacturing cost is reduced, but solubility and dissolution rate are insufficient
Solution Approach 1:
The patent creates a composite self-emulsifying composition containing dutasteride, oil, and surfactant that forms a fine emulsion particle structure when adsorbed to porous excipient. This composite material provides enhanced solubility and dissolution rate comparable to liquid formulations while maintaining solid tablet form, thus resolving the contradiction between manufacturing cost reduction and solubility maintenance
Solution Approach 2:
The patent changes the physical and chemical parameters of the formulation by creating a self-emulsifying system that forms fine emulsion particles (5-50 μm) upon contact with water. This parameter change enables solid preparations to achieve solubility enhancement previously only available in liquid formulations, thus resolving the contradiction between solid formulation cost benefits and solubility requirements
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solid preparation achieves high solubility and bioavailability, ensuring rapid and uniform drug release, making it suitable for formulations like tablets or hard capsules, with dissolution rates and bioavailability equivalent to or greater than AVODART soft capsules.
Implementation Method 1
a porous excipient having a controlled pore structure, which facilitates rapid dissolution and bioavailability by forming a coating film that blocks narrow pores
Implementation Method 2
A solid preparation comprising a self-emulsifying composition of dutasteride, oil, and surfactant, coated with a porous excipient
Data Source
AI summary
The present invention provides a solid preparation comprising, based on 100 parts by weight of the solid preparation, a self-emulsifying composition comprising 0.1 to 0.5 parts by weight of dutasteride, 6 to 110 parts by weight of oil and 6 to 110 parts by weight of a surfactant, and 5 to 185 parts by weight of a coating excipient having pores accommodating the self-emulsifying composition formed in a surface thereof, and a method of manufacturing the solid preparation.